The European Commission has approved Roche and ImmunoGen's Kadcyla, or trastuzumab emtansine, as a treatment for HER-2 positive metastatic breast cancer. The approval was based on data from a late-stage trial that showed Kadcyla improved overall survival, compared with standard therapy. Based on the approval, Roche will pay ImmunoGen a $5 million milestone fee.
Roche-ImmunoGen's breast cancer drug Kadcyla wins EU nod
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|